Template:Map/Ether phospholipid: Difference between revisions

mNo edit summary
No edit summary
 
(10 intermediate revisions by the same user not shown)
Line 1: Line 1:
=Ether Phospholipid Biosynthesis=
=Ether Phospholipid Biosynthesis=
 
エーテルリン脂質の生合成
{|
{|
|-
|-
Line 11: Line 11:
|style="text-align:center;"|1-acyl dihydroxy acetone p
|style="text-align:center;"|1-acyl dihydroxy acetone p
|{{Map/ReactionLeftRight|NADH|NAD+|[http://metabolomics.jp/wiki/Enzyme:1.1.1.8 1.1.1.8]}}
|{{Map/ReactionLeftRight|NADH|NAD+|[http://metabolomics.jp/wiki/Enzyme:1.1.1.8 1.1.1.8]}}
|style="text-align:center;"|1-acyl ''sn''-glycerol 3p
|style="text-align:center;"|1-acyl ''sn''-glycerol 3p<br/>[[Image:LBG1C3P.png]]
|-
|-
|{{Map/ReactionDown35|R1-OH|<small>&rarr;R-COOH</small>|}}1-alkyl dihydroxy acetone p<ref>アルキル型を含むエーテルリン脂質はペルオキシソームで合成。ペルオキシソームを欠乏するZellweger症候群では血小板活性化因子PAFが著しく減少。</ref>{{Map/ReactionDown35|NADPH|<small>&rarr;NADP+</small>|}}
|{{Map/ReactionDown35inout|R1-OH|<small>&rarr;R-COOH</small>|}}1-alkyl dihydroxy acetone p<ref>アルキル型を含むエーテルリン脂質はペルオキシソームで合成。ペルオキシソームを欠乏するZellweger症候群では血小板活性化因子PAFが著しく減少。</ref>{{Map/ReactionDown35inout|NADPH|<small>&rarr;NADP+</small>|}}
|
|
|style="text-align:center;"|[[Image:Arrow00d.png]]
|style="text-align:center;"|[[Image:Arrow00d.png]]
|-
|-
|1-alkyl ''sn''-glycerol 3p
|style="text-align:center;"|1-alkyl ''sn''-glycerol 3p<br/>[[Image:LBG1K3P.png]]
{{Map/ReactionDown|R2-CO-CoA|CoA|[http://metabolomics.jp/wiki/Enzyme:2.3.1.51 2.3.1.51]}}
{{Map/ReactionDown|R2-CO-CoA|CoA|[http://metabolomics.jp/wiki/Enzyme:2.3.1.51 2.3.1.51]}}
|
|
|1-acyl ''sn''-glycerol 3p
|style="text-align:center;"|1-acyl ''sn''-glycerol 3p<br/>or lyso-phosphatidate<br/>
{{Map/ReactionDown|R2-CO-CoA|CoA|[http://metabolomics.jp/wiki/Enzyme:2.3.1.51 2.3.1.51]}}
{{Map/ReactionDown|R2-CO-CoA|CoA|[http://metabolomics.jp/wiki/Enzyme:2.3.1.51 2.3.1.51]}}
|-
|-
|1-alkyl 2-acyl ''sn''-glycerol 3p
|style="text-align:center;"|1-alkyl 2-acyl ''sn''-glycerol 3p<br/>[[Image:LBG1K2C3P.png]]
{{Map/ReactionDown|H2O|Pi|[http://metabolomics.jp/wiki/Enzyme:3.1.3.4 3.1.3.4]}}
{{Map/ReactionDown|H2O|Pi|[http://metabolomics.jp/wiki/Enzyme:3.1.3.4 3.1.3.4]}}
|
|
|1-acyl 2-acyl ''sn''-glycerol 3p
|style="text-align:center;"|1,2-diacyl ''sn''-glycerol 3p<br/>or phosphatidate<br/>[[Image:LBGPA.png]]
{{Map/ReactionDown|H2O|Pi|[http://metabolomics.jp/wiki/Enzyme:3.1.3.4 3.1.3.4]}}
{{Map/ReactionDown|H2O|Pi|[http://metabolomics.jp/wiki/Enzyme:3.1.3.4 3.1.3.4]}}
|-
|-
|1-alkyl 2-acyl ''sn''-glycerol<br/>
|style="text-align:center;"|1-alkyl 2-acyl ''sn''-glycerol<br/>
{{Map/ReactionDown35|CDP-choline|}}
{{Map/ReactionDown35|CDP-choline|}}
platelet-activating factor (PAF; 2=acetyl)<br/>or plasmalogen<ref>プラスマローゲン(不飽和エーテルリン脂質)は飽和エーテルリン脂質の脱水素で生成。</ref>
platelet-activating factor (PAF; 2=acetyl)<br/>or plasmalogen<ref>プラスマローゲン(不飽和エーテルリン脂質)は飽和エーテルリン脂質の脱水素で生成。</ref>
|
|
|1,2-diacyl ''sn''-glycerol<br/>
|style="text-align:center;"|1,2-diacyl and triacyl ''sn''-glycerol<br/>
[[Template:Map/Glycerophospholipid|To GPL biosynthesis
&rarr; [[Template:Map/Glycerophospholipid|<font style="background-color:skyblue">GPL biosynthesis</font>
]]
]]
|}
|}


<references/>
<references/>

Latest revision as of 07:08, 3 July 2009

Ether Phospholipid Biosynthesis

エーテルリン脂質の生合成

dihydroxy acetone p
Arrow3ld.png
R1-CO-CoA
2.3.1.42
CoA
1.1.1.8
Arrow6dh.png
NADH   NAD+
sn-glycerol 3p
Arrow3ld.png
R1-CO-CoA
2.3.1.15
CoA
1-acyl dihydroxy acetone p 1.1.1.8
Arrow6dh.png
NADH   NAD+
1-acyl sn-glycerol 3p
LBG1C3P.png
Arrow3ld35.png
R1-OH
→R-COOH
1-alkyl dihydroxy acetone p[1]
Arrow3ld35.png
NADPH
→NADP+
Arrow00d.png
1-alkyl sn-glycerol 3p
LBG1K3P.png
Arrow3ld.png
R2-CO-CoA
2.3.1.51
CoA
1-acyl sn-glycerol 3p
or lyso-phosphatidate
Arrow3ld.png
R2-CO-CoA
2.3.1.51
CoA
1-alkyl 2-acyl sn-glycerol 3p
LBG1K2C3P.png
Arrow3ld.png
H2O
3.1.3.4
Pi
1,2-diacyl sn-glycerol 3p
or phosphatidate
LBGPA.png
Arrow3ld.png
H2O
3.1.3.4
Pi
1-alkyl 2-acyl sn-glycerol
Arrow1ld35.png CDP-choline

platelet-activating factor (PAF; 2=acetyl)
or plasmalogen[2]

1,2-diacyl and triacyl sn-glycerol

GPL biosynthesis

  1. アルキル型を含むエーテルリン脂質はペルオキシソームで合成。ペルオキシソームを欠乏するZellweger症候群では血小板活性化因子PAFが著しく減少。
  2. プラスマローゲン(不飽和エーテルリン脂質)は飽和エーテルリン脂質の脱水素で生成。